Search Results

tyrosine kinase IGF1R and its associated GPCRs are co-regulated by the noncoding RNA NEAT1 in Alzheimer's disease characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer's disease assays Generation of a deep mouse brain spectral library for transmembrane proteome profiling in mental disease

Abstract submission for oral presentations closes at 11:30 pm EST today! Abstract submission for poster presentations closes at 11:30 pm EST on August 30, 2023. Share your project in an informal setting with a 1-minute abstract video using this form. Submit poster abstracts using this form; short talks will be selected from submissions. Classified GPCR News from August 14 to 20, 2023 Adhesion GPCRs Amelioration of non-alcoholic fatty liver disease

UdM”), to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease

D2LR, D3R, and D4R, vasopressin V1AR, and serotonin 5-HT1AR are noted in various neurodegenerative diseases antagonism, kurarinone might be a potential compound that can alleviate clinical symptoms of Parkinson's disease

signaling and the AMPK and TOR pathways, and those that alter oxidative homeostasis and severe and/or chronic

plant-like” behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Neuroscience Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease Identification of immune-related hub genes in spinal cord injury GPCRs in Oncology and Immunology

fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases

therapeutic strategies aimed at targeting specific phosphorylation events to modulate G protein signaling in disease our understanding of cellular signaling dynamics and open new avenues for therapeutic intervention in diseases

News GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary

regulation of B2R, which shed light on structure-based drug design for the treatment of B2R-related diseases

novel mechanism providing diversity to receptor function and play important roles in physiology and disease

GPCR Symposium on 'GPCRs as Therapeutic Modalities' Showcase your project with a 1-minute abstract video You can submit your poster abstracts using this form and short talks will be selected from abstracts. Please remember that the early-bird registration deadline ends tomorrow, the abstract submissions deadline A case for (mutant) G protein-coupled receptors Reviews, GPCRs, and more RGS2 and female common diseases

GPCRs, including β2AR, play key roles in various conditions, such as asthma, cardiovascular diseases, These insights have the potential to advance the treatment of various diseases involving GPCR signalling

advanced our understanding of rod outer segment (ROS) morphology and the pathological basis of retinal diseases

Share your project with a 1-minute abstract video using this form. Submit poster abstracts via this form; short talks will be selected. Early-bird registration deadline is September 8, abstract submissions close on October 2, and final registration Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases

Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases

for their work on GPCR gene variants and human genetic disease Ilana Kotliar , Thomas Sakmar , et al. Intelligence Reviews, GPCRs, and more G protein-coupled receptor (GPCR) gene variants and human genetic disease

Recent evidence indicates that GPR15 may be associated with modulation of the chronic inflammatory response

Promising preclinical data support the applicability of CB2 activation in autoimmune and inflammatory diseases

significance in GPCR internalization dynamics, internalization routes, postinternalization fates, and related diseases

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases

Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Manager Director of Molecular Pharmacology, Discovery Biology Staff Scientist/Senior Staff Scientist, Disease

The levels of chemerin in circulation are correlated with certain disease conditions, such as patients

Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

contribute to the implementation of the guidelines, together improving translation from in vitro to disease-relevant

study in Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease

pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson’s disease , and Alzheimer’s disease.

for developing therapeutic agents that target specific receptor dimer states to modulate signaling in diseases Perreault, M.L., et al., Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease